All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Moxetumomab pasudotox-tdfk approved by FDA for the treatment of HCL
On 13 September 2018, the US Food and Drug Administration (FDA) announced the approval of moxetumomab pasudotox-tdfk (Lumoxiti) intravenous injection for the treatment of adult patients with relapsed or refractory (R/R) hairy cell leukemia (HCL) after two prior lines of systemic therapies, including treatment with a purine nucleoside analog.
Moxetumomab pasudotox-tdfk is a CD22-directed cytotoxin that was granted priority review by the FDA on 03 April 2018. The approval follows data from the phase III trial (NCT01829711) in which the overall response rate was 75% (95% CI: 64,84) and durable complete response rate of 30% (95% CI: 20,41).
The FDA noted that common side effects of Moxetumomab pasudotox-tdfk included infusion-related reactions, swelling, nausea, fatigue, headache, fever, constipation, anemia and diarrhea. There is a risk of developing capillary leak syndrome and haemolytic uremic syndrome. Additionally, moxetumomab pasudotox-tdfk is not recommended in patients with severe renal impairment.
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?